Journal article

Health behaviours of community-treated patients with psychosis

Gabriel Feiler, Roger Chih-Yu Chen, Christos Pantelis, Timothy Lambert

Australasian Psychiatry | SAGE PUBLICATIONS LTD | Published : 2012

Abstract

OBJECTIVE: To assess physical health self-reports and health utilization behaviours of community dwelling persons with persistent psychosis. METHOD: A cross-sectional survey was conducted of 106 patients with persistent psychosis. Using self-reported measures, the prevalence of smoking, alcohol consumption and exercise, and body mass index were determined. Health utilization behaviour, especially with respect to general practice, was assessed. Data was compared with that derived from the general population and longitudinally with a historical cohort. RESULTS: Compared with the general population, those with psychosis were more likely to be smokers, overweight or obese, and less likely to be ..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

We thank Eleanor Page and Lauren Hoyles for their work in collecting and preparing the data. This research work was made possible by an unrestricted research grant from Eli Lilly AustraliaThe authors alone are responsible for the content and writing of the paper. RC, CP and TL have received honoraria for teaching, research, travel grants and attendance at advisory meetings from pharmaceutical companies. In the last 5 years, RC has received grant and educational support, been on speaker bureaux or advisory boards for Novo Nordisk, Eli Lilly, Sanofi Aventis, Glaxo Smith Kline, Astra Zeneca, Pfizer, Bristol Myers Squibb, Servier, Novartis, Janssen Cilag, MSD, Amgen and Roche Diagnostics. lathe last 5 years, TL has been on speaker bureaux, advisory boards and/or recipient of investigator initiated grants from Janssen Cilag, Eli Lilly, Hospira, Pfizer, Bristol Myers Squibb, Otsuka and Astra Zeneca. In the last 5years, CP has received grant support from Janssen-Cilag, Eli Lilly, Hospira (Mayne) and Astra Zeneca; he has provided consultancy to Janssen-Cilag, Eli Lilly, Hospira (Mayne), Astra Zeneca, Pfizer, Schering Plough and Lundbeck, and he has undertaken investigator initiated studies supported by Eli Lilly, Hospira, Janssen Cilag and Astra Zeneca. GF has no affiliations to declare.